Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC€™s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Drug Discovery Head Jay Bradner On What NIBR Is Investing In

Executive Summary

NIBR's Bradner talked to Scrip about how AveXis turbo-charged Novartis' gene therapy development, investing in inflammasome research, and partnering nimbly like a venture capitalist.

You may also be interested in...



IFM Therapeutics ‘Lather, Rinse, Repeat’ Strategy On Track With $55M Financing

The drug discovery company with a big pharma deal-making track record is launching a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery. Scrip talked to IFM's new CEO Martin Seidel about what is ahead for the company.

Roche Dealmakers On The Immunology Technology They're Shopping For

Business development execs Patrick Schleck and Michael Crowley talk to Scrip about the company’s recent deals with Parvus, Jecure and Microbiotica in the inflammatory and autoimmune disease space.

It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug

The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC125314

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel